secwatch.observer — SEC 8-K summary
======================================

Issuer:     Imunon, Inc. (IMNN)
CIK:        0000749647
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001493152-23-040802
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Imunon Q3 net loss $3.5M; OVATION 2 shows 33% PFS improvement, OS benefit
-------------------------------------------------------------------------

- Net loss of $3.5M ($0.37 per share) vs $6.1M loss in Q3 2022; operating expenses down 38% to $3.9M.
- Cash and equivalents $19.5M as of Sept 30, 2023; expects $1.8M from NJ NOL sales.
- Interim OVATION 2 data: PFS improved ~33% in treatment arm; OS improved ~9 months; median PFS 23.7 months with PARP inhibitor combo vs 15.7 months control.
- Enrolled first patient in Phase 1/2 trial of IMNN-001 + bevacizumab at MD Anderson; IND filing for IMNN-101 COVID booster on track for Q1 2024.
- Entered CRADA with NIAID for Lassa virus vaccine evaluation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/749647/000149315223040802/0001493152-23-040802-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/749647/000149315223040802/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-040802

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer